MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21

CANNANNEW REPORT

MyMD is pursuing high value opportunities in a massive healthcare market with no known competing FDA-approved drugs for treating aging disorders and extending healthy lifespan BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will discuss the multiple indications for each of MyMD’s novel drug candidates, MYMD-1 and Supera-CBD. A webcast of the presentation will be available live and on demand for 90 days after the conference. About MYMD-1 MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. MYMD-1 has shown effectiveness in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. MyMD expects to launch two Phase 2 trials during…

Excerpt only …
READ MORE BELOW
Source : MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.